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Elevated triglycerides levels are an independent risk factor for the development of 
cardiovascular and metabolic diseases. Approximately one third of the American population 
suffers from hypertriglyceridemia. Lipoprotein lipase (LPL) is the rate-limiting enzyme for the 
hydrolysis of triglycerides from triglyceride rich lipoproteins (TRLs), which circulate in the 
blood. LPL also promotes clearance of circulating triglycerides by catalyzing the uptake of 
TRL remnant particles into the liver. For both its role in catalysis and lesser recognized role 
in lipoprotein uptake, LPL is an attractive therapeutic target for reducing circulating 
triglyceride levels and the subsequent risk of cardiovascular disease.  
Studies to understand LPL function have thus far been limited by protein yields, 
particularly for human LPL. This thesis focuses on work undertaken to better understand the 
elements that contribute to LPL’s successful function.  First, I focused on pinpointing the 
benefit of a known, gain-of-function mutation, LPLS447X. LPLS447X is used in LPL gene 
therapy, but until now, there had been no clear mechanistic explanation for its gain-of-
function. I next describe a new method for measuring LPL interactions and dynamics, using 
total internal reflection fluorescence microscopy to monitor single molecules of LPL. Finally, 
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CHAPTER 1: INTRODUCTION TO LIPOPROTEIN LIPASE 
 
Biological Function of Lipoprotein Lipase 
Cardiovascular disease (CVD) is the leading cause of death both in the 
United States of America, and worldwide. Risk factors for developing CVD include 
smoking, physical inactivity, diet, metabolic syndromes such as diabetes, and blood 
lipids levels. In addition to high cholesterol, sustained high triglyceride (TG) levels in 
the blood are also an identified marker of increased CVD risk(1). 
High circulating levels of TG often result from environmental factors, such as 
diet. In rare cases they can result from genetic mutations resulting in loss of 
lipoprotein lipase (LPL) activity. LPL is the rate-limiting enzyme responsible for 
hydrolysis of TGs from circulating TG-rich lipoproteins (TRLs). LPL also serves a 
lesser recognized role as a catalyst for the uptake of lipoproteins from the blood into 
the liver(2-5).  
Genetic mutations leading to diminished LPL function lead to severe 
hypertriglyceridemia. LPL deficiency not only results from over 100 known LPL 
mutations(6), but also from genetic mutations in necessary LPL-interacting factors 
including lipase maturation factor 1 (Lmf1)(7), apolipoprotein CII (APOC-II), 
apolipoprotein AIV (APOA-V), and glycosylphosphatidylinositol anchored high-





Description of LPL Structure/Function 
LPL is a 55 kDa secreted lipase that is active as a head-to-tail homodimer(9). 
Lipases are serine-hydrolases classified as such based on their requirement for 
interfacial activation. Interfacial activation occurs when an enzyme is most active at 
an interface between lipid and water. 
LPL belongs to the lipase gene family, a group of sequence similar secreted 
lipases. Of these proteins, endothelial lipase (EL), hepatic lipase (HL), and LPL are 
dimeric. The fourth member of the family, pancreatic lipase (PL) is monomeric, but 
functions with the assistance of colipase(10-13). While no experimental x-ray 
structure for LPL exists, PL is 30% identical and therefore provides a good homology 
model for LPL.  
Figure 1.1 shows a model of LPL generated using I-TASSER(14-17). Known, 
functionally important domains of the protein are highlighted. LPL is comprised of 
two major domains, linked by a small linker region. LPL’s C-terminus is primarily a 
regulatory domain comprised of beta-sheets. Several binding sites for LPL’s 
interacting partners have been identified within the C-terminus, including heparin 
sulfates, GPIHBP1(18), and lipoprotein receptor-related protein (LRP) (5,19). In 
addition, several tryptophan residues that are critical for lipoprotein binding are 
clustered within LPL’s C-terminus(20). 
LPL’s N-terminal domain contains the catalytic triad active site which is 
covered by a helical loop termed the “lid”. Lipase lids often move in response to 




chain triglycerides(21) and mediating substrate specificity for triglycerides versus 
phospholipids(22,23). It has been shown that several tryptophans on LPL’s C-
terminus mediate substrate binding for the opposite monomer’s active site(24). 
Specifically, the ability of one LPL oligomer to hydrolyze long-chain TG substrates is 
dependent on the intact lipoprotein binding domain of the other. Short-chain 
substrates are not restricted by lipoprotein binding, nor by replacement of LPL’s lid 
by a short linker(24,25). These findings suggest that LPL’s lid is not necessary for 
proper LPL catalysis of all substrates. 
 
LPL’s Regulation by Interaction Factors 
 Proper utilization of energy (fats and sugars) is critical to maintaining 
homeostasis during fasting, feeding, and exercise. Maintaining stable, yet healthy, 
levels of fat in lipoproteins circulating in the blood provides the body with energy on 
demand, and requires tight regulation of LPL. Further, LPL is an unstable protein 
that relies on many interacting partners to maintain activity in vivo and in vitro. As 
shown in Figure 1.2, the different types of LPL-interacting factor interactions can be 
classified as LPL processing, binding/stabilization, inactivation, and activation. 
 
Posttranslational Control of LPL Folding and Secretion 
Following translation, LPL requires the assistance of a special chaperone, 
LMF1 for proper folding and secretion from the endoplasmic reticulum(7,26,27). LPL 
has ten cysteine residues, all of which are contained in five required disulfide bonds, 




LPL processing. The precise mechanism by which LMF1 controls the LPL folding 
process is ongoing work in the Neher Lab, but we believe that LMF1 plays a role in 
supporting quality control for proper LPL folding. 
Following proper glycan trimming the Golgi, LPL is secreted into the interstitial 
space from where it is then translocated to the capillary lumen by GPIHBP1(8). 
GPIHBP1 has binding sites for both LPL and lipoproteins and therefore likely helps 
LPL come in contact with its substrates. 
 
LPL Activation 
The surface’s of lipoproteins are decorated with apolipoproteins, which 
regulate LPL activity, lipoprotein uptake, and a variety of other functions, including 
many which are not well characterized. Among the apolipoproteins, loss of function 
of either APOC-II or APOA-V have been identified to result in a phenotype similar to 
LPL deficiency. This phenotype could be caused by either the apolipoproteins 
catalyzing LPL activity or lipoprotein uptake (29-31).  
Intriguingly, while APOC-II is fairly abundant on the surface of lipoproteins, 
APOA-V is present in circulation at sub-lipoprotein levels (32). APOA-V has been 
poorly studied, but one report suggests that APOA-V is a poor activator of LPL and 
might instead assist in triglyceride turnover by bridging the interaction between 
surface bound LPL and lipoproteins(31). In contrast, studies suggest that APOC-II 
directly activates LPL(33).  
Previous reports show that APOC-II increases the VMAX of LPL(33). An 




been identified. One group has used the activating portion of APOC-II to develop 
APOC-II mimetic peptides that are capable of rescuing APOC-II deficiency in 
mice(36), however, no therapies are currently approved for APOA-V or APOC-II 
deficiency in humans. 
 
LPL Inactivating Factors 
In addition to the apolipoproteins that activate LPL, apolipoprotein C1 (APOC-
I) and C3 (APOC-III) are also known to inhibit LPL (37-41) as well as another family, 
of secreted macromolecular inhibitors, angiopoietin-like proteins (ANGPTL) 3, 4, and 
8 (37,42). Like APOC-II and APOA-V, these inhibitors likely function by inhibiting 
LPL catalysis, lipoprotein binding and/or uptake.  
APOC-I and APOC-III both are capable of inhibiting LPL in vitro on 
lipoprotein-like particles(40). It was recently shown that these apolipoproteins 
displace LPL from the surface of lipoproteins(41), and thus reduce LPL mediated 
lipoprotein receptor uptake, leading to increased circulating lipoproteins. Thus, 
instead of inhibiting LPL, their mode of action is primarily believed to be through 
inhibiting lipoprotein uptake into the liver(39).  
APOC-I was also reported to inhibit lipoprotein binding to LRP in an LPL 
independent fashion(39). Further, APOC-I has been shown to prevent free fatty acid 
(FFA) esterification and uptake into cells (43). APOC-I knockout mice however did 
not benefit from cardioprotective phenotypes(44), and thus APOC-I has not yet been 




APOC-III was found to be a more potent inhibitor than APOC-I(40) and has 
been a recent target for therapeutics. Volanesorsen is an antisense therapeutic 
oligonucleotide that targets APOC-III mRNA, and it is currently in phase three clinical 
trials(45,46). This treatment works by lowering APOC-III plasma concentrations, 
which has been successful in decreasing circulating TG levels.  
The ANGPTL family of proteins are tissue-specific regulators of LPL activity 
that are known to directly inhibit LPL activity. Loss of either ANGPTL 3 or 4 results in 
low plasma triglyceride levels in mice(47,48), but not ANGPTL8(49). ANGPTL8(50) 
is the newest member of the ANGPTL family, and it is believed to require ANGPTL3 
for activation, while ANGPTL3 can act alone to inhibit LPL(49,51). Antibodies 
reducing ANGPTL8 show reduced plasma triglycerides in mice(52), suggesting 
ANGPTL8 still plays a key role in LPL inhibition. ANGPTL4, however, is the most 
potent LPL inhibitor of the family and like LPL is found in the blood, and as a result, it 
is the best studied family member.  
It was previously believed that ANGPTL4 inhibited LPL by acting as an 
unfolding chaperone, but our group found that ANGPTL4 inhibits LPL by acting as a 
reversible non-competitive inhibitor of LPL(53). Based on their high similarity and 
conservation of an LPL-inhibitory motif, the other members of the ANGPTL family 
likely inhibit LPL by a similar mechanism.  
The finding that ANGPTL4 is a reversible inhibitor has paved the way for a 
new avenue of triglyceride lowering drugs aimed at disturbing the LPL/ANGPTL4 
bond. The question of where ANGPTL4 binds and inhibits LPL in vivo remains an 




LPL/ANGPTL4 interaction may require specific delivery to the plasma because 
ANGPTL4 is also believed to inhibit PL in the intestines(54). Inhibition of PL would 
be expected to increase fat adsorption into the intestine which in turn would increase 
circulating fat levels, but a previous study showed that carriers of loss-of-function 
ANGPTL4 mutations have a lower incidence of cardiovascular disease(55).  
One group showed that LPL is protected from inhibition from ANGPTL3 and 
ANGPTL4 when LPL is bound to triglyceride rich lipoproteins(56), but conflicting 
data exists for inhibition of GPIHBP1 bound LPL. One study showed protection of 
LPL inhibition, by GPIHBP1, in vitro(57) while another showed that the addition of 
ANGPTL4 removes LPL from the outside of GPIHBP1 expressing cells in 
culture(58). Disruption of the LPL/GPIHBP1 interaction by ANGPTL4 suggests that 
an ANGPTL4 targeting therapeutic would need to target ANGPTL4 before it can 
disturb LPL on capillaries  
Specific open research questions include how these protein inhibitors bind to 
LPL, how they affect its oligomeric state and if they cooperate to ensure appropriate 
physiological regulation of LPL’s activity. 
 
Therapeutic Strategies to Improve LPL Function 
For patients suffering from severe hypertriglyceridemia due to familial lipase 
deficiency, a gene therapy drug, Alipogene Tiparvovec, is available in Europe(59). 
The LPL gene packaged in Alipogene Tiparvovec is for a slightly truncated version 
of LPL, LPLS447X, which is the only characterized LPL gain-of-function mutation. Until 




several hypotheses have been tested. I have shown, as follows in the next chapter, 
that it is likely due to improved lipoprotein uptake(60). Improved lipoprotein uptake 
explains the striking difference in triglyceride levels seen in previous studies as each 
lipoprotein particle holds huge quantities of un-hydrolyzed triglycerides, so any small 
increase in uptake contributes greatly to TG clearance. 
Alipogene Tiparvovec is the only approved therapy for LPL deficiency, only 
approved for use in Europe, and it only is suitable for patients with LPL gene 
perturbations, but not perturbations in genes such as APOC-II, APOA-V, LMF1, and 
GPIHBP1. Unfortunately, the million-dollar price-tag and reduced efficacy over a 
short period of time(61-63) make Alipogene Tiparvovec a poor option for treating 
LPL deficiency. While LPL deficiency due to homozygous mutation is relatively rare 
(<1%)(64), heterozygous LPL mutations that may reduce overall LPL function are 
fairly common and can contribute to increased CVD risk through reduced triglyceride 
hydrolysis and redistribution of smaller lipoproteins. To address impaired LPL 
function due to genetic and environmental factors, as well as in patients with high 
triglyceride levels not resolvable by current interventions, novel therapies are 
necessary.  
 Recent studies have focused on enhancing LPL activity by blocking its 
inhibition(45,65,66), activating catalysis(36,67), or stabilizing the enzyme(68). 
Despite the large number of known LPL regulatory proteins, the precise mechanisms 
by which many of these proteins interact with LPL, and their combined effects, 




deeper understanding of LPL’s function and structure would improve approaches to 
target LPL with therapeutics.  
 
 
Figure 1.1 Structural Model of LPL 
An I-TASSER(14-17) generated model of LPL threaded on the crystal 
structure of pancreatic lipase(10), a lipase with 30% sequence identity to LPL. LPL’s 
N-terminus (light purple) contains the lid (dark grey), catalytic triad (dark red), N43 
glycosylation site (blue), and a lower-affinity part of the heparin binding site. The C-
terminal (light blue) contains LPL’s heparin binding site (light orange), GPIHBP1 









Figure 1.2 LPL is Highly Regulated by Different Groups of Interacting Proteins 
LPL undergoes tight regulation through interaction with many protein partners. 
Shown here is a diagram representing the different ways in which LPL interacting 








CHAPTER 2: BIOCHEMICAL ANALYSIS OF THE LIPOPROTEIN LIPASE 




Nearly one third of the American population has elevated triglyceride (TG) 
levels, leading to increased risk for cardiovascular disease(69). Lipoprotein lipase 
(LPL), an obligate homodimeric enzyme, is the primary enzyme responsible for 
hydrolysis of circulating TG-rich lipoproteins. Although most identified mutations in 
the LPL gene are deleterious, one mutation, LPLS447X, has been reported as a gain-
of-function mutation(70). LPLS447X is truncated by two amino acids at the C-terminus, 
which results in the loss of a serine and glycine. Intriguingly, studies comparing 
human LPLS447X carriers to non-carriers report that carriers have a reduced 
incidence of myocardial infarction, and a favorable lipid profile highlighted by 
decreased TG and increased HDL(71-73). An analysis of LPLS447X carriers who 
participated in the Framingham Heart Study found that approximately 17% of the 
American population carries at least one copy of the truncated LPL. Additionally, 
                                            
1 This chapter adapted from the previously published work: Hayne, C. K., Lafferty, M. J., Eglinger, B. 
J., Kane, J. P., and Neher, S. B. (2017) Biochemical Analysis of the Lipoprotein Lipase Truncation 
Variant, LPLS447X, Reveals Increased Lipoprotein Uptake. Biochemistry 56, 525-533  
Reprinted with permission from BIOCHEMICAL ANALYSIS OF THE LIPOPROTEIN LIPASE 
TRUNCATION VARIANT, LPLS447X, REVEALS INCREASED LIPOPROTEIN UPTAKE. Copyright 




male carriers showed an average of 13.8% reduction in TG levels whereas female 
carriers do not show changes in TG levels(72). Average TG reduction varies by 
study, and some studies identify female carrier populations with reduced TG 
levels(71). 
Results from mouse studies were similar. LPL-/- mice rescued by retroviral 
treatment with LPLS447X showed significantly lower triglyceride levels than LPL-/- mice 
treated with LPL(74). In that study, LPLS447X and LPL protein levels did not 
significantly differ, whereas the activity of LPLS447X was two times that of LPL. 
Despite the strong in vivo evidence from both mice and humans demonstrating that 
LPLS447X is a gain-of-function mutation, the precise mechanism by which LPLS447X is 
beneficial remains unclear. Past studies have compared the production, stability, 
and activity of LPLS447X and LPL and cannot explain the in vivo phenomena(74-76).  
In contrast to the in vivo studies, in vitro reports vary as to whether the LPL 
variants have different activity. Measurements of proteins in tissue culture media 
showed that LPLS447X had increased(77), decreased(76,78), or no difference(79,80) 
in activity. Many of these studies used LPL quantified by ELISA to determine protein 
mass, whereas others use Western blots. These methods do not account for the 
inactive pools of LPL, which comprise the majority of the protein in media. Inactive 
LPL includes LPL that has undergone cleavage by proprotein convertases and 
monomeric LPL that can no longer dimerize(21,81). Further, the studies evaluated 





One explanation for LPLS447X's observed in vivo gain-of-function could be 
changes in binding affinity between LPL and one or more of its interacting factors. 
Glycosylphosphatidylinositol anchored high-density lipoprotein binding protein 1 
(GPIHBP1)(18) and lipoprotein receptor-related protein (LRP)(19) are both known to 
interact with the C-terminus of LPL, and could thus interact differently with LPLS447X. 
GPIHBP1 is the protein responsible for translocation of LPL to the capillary lumen, 
and a recent study showed that its binding affinity for LPLS447X was not altered, which 
suggests another factor may be the key to the difference(8,79). LRP is a receptor for 
the endocytosis of ApoE-containing lipoproteins, and LPL enhances LRP-mediated 
lipoprotein uptake(2,82,83). In support of this idea, a previous report by one group 
indicates an increase in clearance of lipoproteins in LPLS447X carriers(84). We thus 
investigated the possibility that the benefits of LPLS447X are not linked to enzymatic 
activity, but instead in how LPL bridges lipoprotein uptake.  
An alternate explanation for enhanced LPLS447X function is differences in how 
the two LPL variants are regulated by circulating activating and inactivating factors. 
Angiopoietin-like protein 4 (ANGPTL4) and apolipoproteins regulate LPL, but the 
specific binding sites on LPL are not known. We recently showed that ANGPTL4 
inhibits LPL by a non-competitive mechanism(53). Because the ANGPTL4-binding 
region(s) on LPL are unknown, we hypothesized that ANGPTL4 might have 
decreased binding to the truncated variant of LPL, which would allow LPL to be 
more active in vivo. Alternatively, other alterations in binding may occur between 




LPLS447X would have altered activity in vivo because key binding partners are 
present.  
Here, we aim to understand the advantageous characteristics of LPLS447X 
observed in vivo using biochemical assays to compare LPL and LPLS447X activity 
alone and in the presence of various binding partners. We find that LPL and 
LPLS447X have identical catalytic activity on artificial and natural substrates. We did 
not find a significant difference in ANGPTL4 inhibition of LPL, either in the presence 
or absence of GPIHBP1. Finally, we did see a difference in LPL-enhanced uptake of 
lipoproteins by hepatic cells. Modeling the LPLS447X truncation onto the LPL structure 
suggests that loss of these two amino acids may provide enhanced access to the 
LRP receptor-binding site on LPL, which may also be where other lipoprotein uptake 
receptors bind to LPL. In keeping with this hypothesis, we found that LPLS447X bound 
more tightly than LPL to the low-density lipoprotein receptor (LDLR).  
 
Materials and Methods 
Molecular Cloning 
LPL and GPIHBP1 variants were cloned into pCDNA5/FRT/TO (Thermo 
Fisher Scientific). The human and mouse GPIHBP1 constructs included a HIS-tag 
after the cleavage sites, after amino acids 151 and 181, respectively. The cloning of 







Protein Expression and Purification 
LPL and GPIHBP1 expression and secretion were induced by replacing the 
growth medium with in Dulbecco's Modified Eagle Medium (DMEM) containing 1% 
Fetal Bovine Serum, 1% Penicillin-Streptomycin, and 1 mM L-Glutamine, with 20 
µg/mL Tetracycline. For LPL, 10 units/mL Heparin and 1 mM CaCl2 were also 
added.  
LPL was purified over a HiTrap Heparin Sepharose High Performance 
Column (GE Healthcare Life Sciences), washed with 75 column volumes of 850 mM 
NaCl, 10% glycerol, 20 mM Bis-Tris pH 6.5 and eluted with 1500 mM NaCl, 10% 
glycerol, 20 mM Bis-Tris pH 6.5. Protein was concentrated, aliquoted, flash frozen in 
liquid nitrogen, and stored at -80° C until use. For GPIHBP1, the media pH was 
adjusted to >8.0. Media was then incubated with cOmplete His-Tag Purification 
Resin (Roche), washed with buffer (200 mM NaCl, 20 mM Tris 8.0), and eluted with 
buffer + 500 mM Imidazole. ANGPTL4 was purified as previously described(53).  
 
Quantification of LPL Variants 
Bovine LPL of a known concentration, purified as described(85), was used as 
a standard for the quantification of LPL variants. Bovine LPL and the LPL variants 
were incubated for 30 minutes at room temperature with an excess of ActivX 
TAMRA-FP Serine Hydrolase Probe (Thermo Fisher Scientific). Reactions were 
quenched by the addition of loading dye. Samples were loaded onto 12% gels and 
separated by SDS-PAGE. The gel was imaged using a Typhoon Trio+ imager 




ImageQuant TL software was used to quantify band intensities. Concentrations of 
the LPL samples (dimers) were calculated from the bovine LPL standard curve. Only 
unknown concentrations that fell within standard curves with R2 ≥ 0.95 were used in 
activity assays. Samples were quantified in triplicate. The LPL antibody α-4-1a, a 
kind gift from André Bensadoun, was used to demonstrate that the active-site 
labeled protein concentrations were equal to the purified dimer protein 
concentration(86).  
 
Activity Assays for LPL, Using a Fluorescent Lipase Substrate 
Activity assays were carried out essentially as described(53), except that 2.5 
nM LPL was used, assays were carried out at 37 °C, and the first 200 seconds of the 
reaction was used to calculate the initial velocity. Deoxycholate (at 1 mM) was 
included in all reactions to stabilize LPL.  
 
Activity Assays for LPL, Using Plasma-Derived Triglycerides 
Plasma from patients with normal lipid profiles and hyperlipidemia were 
supplied by Dr. John Kane and were collected under protocol # 10-00272 as 
approved by the Institutional Review Board at the University of California at San 
Francisco. Informed consent was obtained from all human subjects. Triglyceride rich 
lipoproteins (TRLs) were isolated as previously described(87). TRLs were quantified 
as previously reported(88). 2.5 nM LPL, final concentration, was incubated with 
isolated lipoproteins in a volume of 30 μL. Individual reactions were quenched at 0, 




Arbor, Michigan, USA) to a final concentration of 150 μM Orlistat in 40 μL. Released 
free fatty acids (FFA) were quantified using reagents previously described(88). Initial 
velocities were calculated by plotting FFA (μM) release against time from 0-9 
minutes. Initial velocities were plotted as a function of substrate concentration and fit 
to the Michaelis–Menten equation using Kaleidagraph to calculate the kinetic 
parameters Vmax and KM. Each LPL sample was assayed at least five times. 
 
Inhibition of LPL by ANGPTL4 
To determine the Ki for ANGPTL4 inhibition of LPL, ANGPTL4 was added to 
dilute LPL at a final volume of 70 μL/reaction. The reaction was initiated by the 
addition of 30 μL of varying levels of DGGR in Anzergent (Affymetrix), to a final 
volume of 100 μL. Samples were shaken in a Spectromax M5 plate reader, set to 
37 °C, for 5 seconds and then substrate hydrolysis was measured by fluorescence 
excitation at 529 nM, emission at 600 nM, and a filter of 590 nM. Final assay buffer 
concentrations were 150 mM NaCl, 1 mM deoxycholate, 20 mM Tris pH 8.0, 0.2 % 
Fatty Acid Free BSA, and 0.01 % Anzergent. Final ANGPTL4 concentrations were 0, 
0.25, 0.5, 1.0, and 2.0 μM. The rate of initial LPL substrate hydrolysis was plotted as 
a function of substrate concentration. Next, data were fit to the equation for 
noncompetitive inhibition: v = Vmax*[S]/{(KM*(1+[I]/Ki))+([S]*(1+[I]/Ki))} where Vmax is 
the uninhibited maximum rate of substrate hydrolysis, KM is the Michaelis-Menten 
constant, [S] is substrate concentration, [I] is inhibitor concentration, and Ki is the 
inhibition constant. Data were fit using simultaneous nonlinear regression with the 




ANGPTL4 Inhibition in the Presence of GPIHBP1 
LPL assays were conducted essentially as described above for the LPL 
activity assays, without the inclusion of deoxycholate because GPIHPBI stabilizes 
LPL. GPIHBP1 (approximately 80 nM final concentration) was pre-incubated with 
LPL diluted in assay buffer before the addition of ANGPTL4 (0.5, 1.0 and 2.0 µM 
final concentration).   
 
Measurement of Low-Density Lipoprotein Uptake 
Clear bottom, black sided 96-well plates were coated with 0.1 mg/mL Poly-D-
Lysine and allowed to incubate for 8 minutes. Wells were then washed three times 
with PBS and the plates were cured under UV light for at least 15 minutes. 
Alternatively, TC-treated 96-well black sided, clear bottom plates were used. HepG2 
cells were seeded and allowed to grow to approximately 90% confluence in DMEM 
containing 10% Fetal Bovine Serum, 1% Penicillin-Streptomycin, and 1 mM L-
Glutamine. Cells were starved for 2.5 hrs in Phosphate Buffered Saline (PBS), and 
then the PBS was replaced with PBS with or without 10 nM LPL (desalted into PBS) 
and 1X LDL-550 (Abcam). Cells were incubated for 30 minutes then washed three 
times with PBS. 50 μL fresh PBS was added to the cells and wells were read for 
fluorescence intensity at 570 nm after excitation with a laser at 540 nm. Each plate 
contained at least triplicate wells for control, LPL, and LPLS447X samples. Data from 
different days was consistent, but to account for small deviations in cell number, 
confluency, and time, samples were normalized to the LDL alone control measured 




Measurement of Very-Low-Density Lipoprotein Uptake 
Huh-7 cells were seeded into TC-treated 96-well black sided, clear bottom 
plates and allowed to grow to near confluence in DMEM containing 10% Fetal 
Bovine Serum, 1% Penicillin-Streptomycin, and 1 mM L-Glutamine. Cells were 
starved for 2 hours in PBS, and then the PBS was replaced with PBS with or without 
20 nM LPL (desalted into PBS) and fluorescently labelled VLDL. VLDL was labelled 
as previously described(89), except 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-
N-(carboxyfluorescein) salt (Avanti) was used for the labeling reagent. Cells were 
incubated with LPL/VLDL mixtures for 30 minutes then washed three times with 
PBS. Fresh PBS was added to the cells and the fluorescence was measured by 
excitation at 494 nM, emission at 515 nM, and a cut-off filter at 515 nM. Each plate 
contained at least four wells per sample, controls, LPL, and LPLS447X samples. Data 
from different days was consistent, but to account for small deviations in cell 
number, confluency, and time, samples were normalized to the LDL alone control 
measured each day. Experiments were conducted on three different days.  
 
LPL Modelling 
Lipoprotein lipase was modeled using the I-TASSER structure prediction 
server(14,16,17). Top threading templates used included human pancreatic lipase 
(2PPL) and horse pancreatic lipase (1HPL). All templates were between 28-30% 
sequence identity and greater than 93% sequence coverage. Despite the high 
sequence coverage, the c-terminal tail residues of LPL (439-448) are not 




the C-terminal tail of LPL, the FloppyTail application within the Rosetta software 
suite was used to determine 1100 possible structural conformations for residues 
439-448(90). The top 10 lowest energy structures (Figure 2.1) were analyzed to 
identify feasible interactions between the C-terminal tail and regions of LPL known to 
play a role in receptor binding. 
 
Analysis of LPL LDR Binding by SPR 
SPR experiments were performed using the ProteOn XPR36 (Biorad) with the 
HTG Sensor Chip and Kit (Biorad). His-tagged LDLR (Invitrogen) was immobilized 
on the chip by flow at 25 μL/min for 120 seconds. Buffer blanks were taken for 60 
seconds at 100 μL/min. Finally, LPL variants at 6.6 and 20 nM were flowed over 
channels with or without LDLR for 100 seconds at 100 μL/min. All measurements 
were carried out at 25 °C in 50 mM Tris 8.0, 400 mM NaCl, 1% glycerol, 0.005 % 
Tween-20, 2 mg/mL BSA, 2 mM CaCl2, and 1 mM deoxycholate. All data was 
collected and analyzed using ProteOn Manager. Buffer and a channel with no LDLR 
were background subtracted from the data. A Langmuir interaction model for 1:1 
binding with simultaneous on/off was used to estimate kinetic parameters.  
 
Results 
LPL and LPLS447X are Equally Active on Natural and Synthetic Substrates 
 LPLS447X could show a gain-of-function phenotype in vivo because it has a 
higher specific activity than LPL. We thus set out to determine if the LPL variants 




LPLS447X. We precisely quantified the amount of active lipase in each preparation 
using an activity based probe(91), which fluorescently labels the active site serine of 
only properly folded, active lipases (Figure 2.2A). We next analyzed lipase activity 
using DGGR, a synthetic substrate that produces a fluorescent signal upon 
hydrolysis. Equal amounts of LPL and LPLS447X were assayed at increasing 
substrate concentrations to complete a full Michaelis–Menten curve. As shown in 
Table 1 and Figure 2.2B and C, LPL and LPLS447X showed no difference in Vmax or 
KM when assayed on DGGR. Thus, from these quantitative kinetic assays using 
purified, precisely quantified LPL variants, LPLS447X does not have an enhanced 
ability to bind or hydrolyze substrate relative to LPL.  
 Because LPLS447X and LPL showed similar specific activity on a synthetic 
substrate, we asked if LPLS447X had enhanced triglyceride hydrolysis activity on a 
natural substrate. Lipoproteins contain apolipoproteins that alter LPL activity. For 
example, APOC-II, a component of VLDL and chylomicrons, activates LPL, whereas 
APOC-III inhibits LPL(37). We thus tested the hypothesis that LPLS447X could be 
more activated or less inhibited than LPL by an apolipoprotein component of its 
natural substrates. Chylomicrons from a patient with severe hypertriglyceridemia 
were used to achieve maximal substrate concentration for a full Michaelis-Menten 
analysis. No difference in Vmax or KM between LPL and LPLS447X was observed on 
chylomicrons (Table 2, Figure 2.3A). In addition, LPLS447X and LPL showed identical 
activity on VLDL purified from a patient with a normal lipid profile (Figure 2.3B). 




these data suggest that there is no difference in the interaction of the LPL variants 
with the apolipoproteins on the surface of the TRLs. 
 
No Significant Difference in ANGPTL4 Inhibition of LPL vs. LPLS447X 
LPL activity is inhibited not only by APOC-III, but also by soluble secreted 
proteins including ANGPTL4. We thus measured the ANGPTL4 inhibition of both 
LPL variants. LPL activity was measured over several substrate concentrations in 
the presence of increasing amounts of ANGPTL4. Data were fit to an equation for 
noncompetitive inhibition. No significant difference in Ki was observed (p-value > 
0.05, Figure 2.4), suggesting that ANGPTL4 does not inhibit LPLS447X more than 
LPL.  
 
No Difference in GPIHBP1-Mediated Protection of LPL vs. LPLS447X Against 
ANGPTL4 Inhibition 
Because ANGPTL4 does not inhibit LPLS447X to a greater extent than LPL, we 
wanted to determine if ANGPTL4 inhibited the two LPL variants differently in the 
presence of GPIHBP1. In a previous study, it was shown that soluble GPIHBP1 
protects LPL from inhibition by ANGPLT4(57). Another study showed that ANGPTL4 
displaces LPL from GPIHBP1(58). Although GPIHBP1 bound equivalently to LPL 
and LPLS447X, it is possible that GPIHBP1 differently protects LPL and LPLS447X from 
inhibition by ANGPTL4(79). We therefore tested the protective effect of GPIHBP1 on 
LPL and LPLS447X inhibition by ANGPTL4. We tested LPL inhibition at three 




Neither LPL variant was preferentially protected against ANGPTL4 inhibition (Figure 
2.5). Thus, ANGPTL4 does not inhibit the two LPL variants differently, even in the 
presence of LPL’s physiological binding partner, GPIHBP1. One unexpected 
outcome of these experiments was that we observed that only truncated mouse 
GPIHBP1, but not truncated human GPIHBP1, was secreted from cells in culture 
(Figure 2.6). Thus, mouse GPIHBP1 was used in these experiments. 
 
LPLS447X Enhances Lipoprotein Uptake to a Greater Extent that LPL 
LPL is responsible for bridging the uptake of LDL and VLDL particles by the 
liver(2,92), through an interaction mediated by the C-terminus of LPL(19,93). We 
measured the ability of LPL and LPLS447X to assist with LPL-mediated lipoprotein 
uptake. Accordingly, we incubated LDL particles conjugated to DyLight-550 with 
cultured HepG2 hepatic cells and measured the resulting fluorescence intensity of 
the cells. We observed that both LPL and LPLS447X increased LDL uptake into the 
HepG2 cells. However, LPLS447X increased LDL uptake more than LPL and this 
difference was significant (p-value < 0.05, Figure 2.7A). To further explore this result, 
we utilized SPR to analyze the interaction between the two LPL variants and the 
LDLRV. These experiments revealed that both LPL and LPLS447X bound to LDLR 
with sub-nanomolar affinity, but LPLS447X binding was several orders of magnitude 
tighter (Figure 2.8).  
LPLS447X also increased uptake of VLDL more than did LPL. To analyze 
uptake of fluorescently labeled VLDL, we used Huh-7 cells as we observed that 




enhanced lipoprotein uptake relative to LPL, and this difference was significant 
(Figure 2.7B, p< 0.05). Thus, our study suggests that the beneficial effect of LPLS447X 
stems at least partly from its ability to more greatly enhance the receptor-mediated 
uptake of lipoproteins by the liver.  
 
Discussion 
The LPLS447X mutation occurs in 10-20% of the population(94). It is different 
from other rare and common LPL mutations in that it has a beneficial effect. 
Although many theories have been proposed and tested, the precise reason that 
loss of these last two amino acids enhances LPL's function is still unknown(71). 
Despite this ambiguity, LPLS447X is used in Alipogene tiparvovec (Glybera), the gene 
therapy product for LPL deficiency(95). Use of LPLS447X for gene therapy is 
supported by a study in mice comparing rescue of LPL deficient mice with LPL vs. 
LPLS447X via adenoviral-mediated gene transfer(74). This study provided strong 
evidence that LPLS447X is a gain of function mutation and that the effect occurs at the 
protein level because the two versions of LPL were expressed in identical adenoviral 
vectors(74). Studies in humans and mice suggest that LPL levels in post-heparin 
plasma are not different between LPL and LPLS447X individuals(74,84,96). Other 
studies note that any differences in plasma protein levels could be explained by the 
use of different LPL antibodies (74). Thus, in the absence of significant differences in 
plasma protein levels, LPLS447X must either have intrinsically higher catalytic activity, 




enhance hepatic uptake of lipoproteins from the blood. As discussed below, we 
provide biochemical evidence that favors the last explanation. 
To date, data showing that LPLS447X has enhanced catalytic activity have 
been contradictory, with studies showing that LPLS447X has increased(77), 
decreased(78), or no difference(79,80) in activity. These disparate results are likely 
due to the fact that these studies used conditioned media as a source of LPL. These 
assays generally use unpurified LPL variants that are quantified via ELISA or 
Western blot. These methods for quantification do not account for the inactive 
monomeric and cleaved populations of LPL, which make up the majority of the 
protein population secreted into tissue culture media. We therefore purified human 
LPL and LPLS447X from conditioned media using heparin-sepharose 
chromatography. We quantified the amount of active LPL using a fluorescent, 
activity-based protein probe that targets serine hydrolases(91). We used the well-
quantified, active LPL in measurements of the hydrolysis of the synthetic substrate 
DGGR. These data show that there is no difference in substrate binding or 
hydrolysis between the variants, nor two C-terminally tagged versions of LPL (data 
not shown). We also tested the idea that the kinetics of substrate binding and 
hydrolysis of LPL’s natural substrates, TRLs, were different than the hydrolysis of 
the synthetic model substrate. LPL’s natural substrates of TRLs are decorated with 
apolipoproteins that regulate LPL activity and particle uptake. Hydrolysis assays 
using TRLs isolated from human serum as substrates showed that LPLS447X does 
not have significantly different hydrolytic activity than LPL. This finding is in 




difference in enzymatic activity between the two LPL variants. Furthermore, these 
findings suggest that the differences seen in vivo do not result from differences in 
the interactions of the LPL variants with lipoproteins during hydrolysis.  
To examine the possibility that the differences between LPLS447X and LPL in 
vivo could be explained by LPL’s interaction with one of its many regulatory factors, 
we tested inhibition by ANGPTL4 both alone and in the presence of GPIHBP1, 
which has been reported to protect LPL from ANGPTL4-mediated inhibition(57). LPL 
and LPLS447X bind to GPIHBP1 equivalently, although residues 421-435 in LPL’s C-
terminus mediate LPL binding to GPIHBP1(18,79). Therefore, the LPLS447X 
truncation could result in less LPL exposed when it is GPIHBP1-bound and thus 
better protection of LPL from inhibition. However, we did not find a significant 
difference in ANGPTL4 inhibition of the two LPL variants, either in the presence or 
absence of GPIHBP1.  
 Independent of its catalytic activity, LPL enhances the receptor-mediated 
uptake of lipoproteins via at least three receptors. LPL enhances the binding, uptake 
and degradation of triglyceride-rich and remnant lipoproteins mediated by the 
LRP(2,82). LPL also enhances the LDL receptor-mediated uptake of LDL 
particles(92), and enhances TRL uptake through the VLDL receptor (VLDLR)(97). 
Previous reports demonstrate that the C-terminal domain of LPL is responsible for 
the interaction with LRP(3-5,19,98). The specific domains of LPL that mediates 
interaction with the VLDL and LDL receptors are not yet known. Using fluorescently 
labeled LDL and VLDL particles, we found that liver-derived cells (HepG2 and Huh-




added. This result is due to enhanced receptor binding by LPLS447X, rather than 
enhanced TRL binding, because both LPL variants had equivalent KM values for 
hydrolysis of TRLs. We also show that LPLS447X binds to the LDLR more tightly than 
does LPL (Figure 2.8). Finally, our results are consistent with a study comparing 
APOB100 metabolism in individuals homozygous for LPLS447X to control subjects, 
which showed that APOB100 LDL clearance was enhanced in homozygous LPLS447X 
individuals(84).  
Further, our findings make structural sense in light of a study by Chappell et 
al.(98) in which the C-terminus of LPL was expressed in E. coli and tested for its 
ability to enhance VLDL uptake. In that study, the authors found that four single point 
mutations in LPL (R405A, K407A, K413A, and K414A) are each sufficient to reduce 
the LPL-enhanced uptake of VLDL particles. Other groups suggest a similar LRP 
binding region on LPL involving residues 390-421(3), 313-448(5), or 380-425(4). In 
Figure 2.1, we modeled LPL’s structure using I-TASSER(14,16,17). Because the C-
terminal tail of LPL was not homologous to any of the threading templates used by I-
TASSER, we further modeled it using the FloppyTail application within Rosetta(90). 
These models suggest that the LRP-binding region on LPL encompassing residues 
405-414 (Figure 2.9, magenta) may be occluded by LPL’s C-terminal tail (Figure 2.9, 
cyan and blue). In particular, amino acids 447 and 448, the amino acids lost in 
LPLS447X, may contribute to binding interactions that stabilize interactions between 
the C-terminal tail and the LPR-binding region (Figure 2.10). We therefore suggest 
that the truncated version of LPL has improved uptake because it provides more 




that LDLR, VLDLR, and LRP all bind to LPL in a similar fashion. LDLR and VLDLR 
share 46% sequence identity and both share homology with LRP through its many 
low density lipoprotein receptor class domain repeats. 
LPLS447X has long been a mysterious gain-of-function mutation. Past 
experimental and population studies have produced contradictory results to explain 
why LPLS447X carriers benefit from a cardioprotective phenotype. Our intensive 
biochemical approach allows us to conclude that the cardioprotective effect of 
LPLS447X is not likely due to a difference in specific activity or interaction with 
apolipoproteins. We observed no significant changes in ANGPTL4 inhibition on 
LPLS447X as compared to LPL, indicating that changes in inhibition are unlikely the 
factor resulting in the changes seen in vivo. Rather, our data support the idea that 
LPLS447X increases LPL-mediated lipoprotein uptake. A model of LPL's structure 
suggests that when LPL's last two amino acids are lost, interactions between LPL's 
C-terminus and a region needed for uptake receptor binding are weakened. As a 
result, the receptor-binding region could be more exposed in LPLS447X as compared 









Figure 2.1. Ten Low-Energy Models of LPL's Tail as Predicted by Floppy-Tail. 
A LPL homology model was predicted by I-TASSER and then modified to have an 
extended tail and used as the starting structure for Rosetta:FloppyTail (gray). 
Possible tail structures (colored) show that the C-terminus of LPL is proximal to 
residues 405-414. Zoomed view shows feasible hydrogen binding interactions 
between the backbone of residues 447 and 448 with the side chain of residue 411 





Figure 2.2. LPL and LPLS447X are Equally Active on the Lipase Substrate DGGR. 
A) An activity based probe was used to quantify the amount of active human LPL and 
LPLS447X using bovine LPL as a standard. The equal concentration of LPL and 
LPLS447X is verified by Western blot using an antibody more sensitive to human LPL.  
B) A Michaelis–Menten curves showing that LPL (filled circles) and LPLS447X (empty 
squares) have identical activity when hydrolyzing a synthetic substrate.   
C) Graph of Vmax and KM values from multiple experiments for both LPL variants. A 
two-tailed student’s t-test showed no significant difference in Vmax (p > 0.05) and KM 







Figure 2.3. LPL and LPLS447X Hydrolyze TRLs Equivalently. 
A) Hydrolysis of chylomicrons by LPL and LPLS447X B) Hydrolysis of VLDL by LPL and 
LPLS447X. A two-tailed student’s t-test showed no significant difference between LPL 
vs. LPLS447X in the Vmax (p > 0.05) and KM (p > 0.05) on chylomicrons. There was not 







Figure 2.4. ANGPTL4 Inhibits LPL and LPLS447X Equivalently. 
Example Michaelis–Menten curves of A) LPL and B) LPLS447X showing inhibition with 
increasing concentrations of ANGPTL4 over multiple substrate concentrations to 
obtain Ki values. Data was fit to an equation for noncompetitive inhibition. C) Data 
from independent experiments performed on different days with different ANGPTL4 
preps is plotted. There is no significant difference in ANGPTL4 inhibition of LPL and 





Figure 2.5. LPL and LPLS447X are Equivalently Inhibited by ANGPTL4 
in the Presence of GPIHBP1. 
LPL and LPLS447X were pre-incubation with GPIHBP1 and then increasing 
concentrations of ANGPTL4 were added, and LPL activity was tested. These 
experiments show that LPL and LPLS447X are equivalently inhibited by ANGPTL4 in 








Figure 2.6 Mature Mouse, but Not Human GPIHBP1 is Secreted from Cells. 
Stable cell lines containing HIS-tagged GPIHBP1 variants or regular HEK cells were 









Figure 2.7. LPLS447X Enhances Uptake of Fluorescent Lipoprotein Particles 
to a Greater Extent than LPL. 
A) Uptake of DyLight-550 labeled LDL by HepG2 cells in the presence of LPL and 
LPLS447X, as compared to no LPL. Randomly selected representative replicates from 
three different days are shown. A two-tailed student’s t-test showed a significant 
difference in LDL uptake mediated by LPL vs. LPLS447X (p << 0.005). Both variants 
showed a significant difference in uptake when compared to the control without LPL. 
B) Uptake of fluorescein labeled VLDL by Huh-7 cells in the presence of LPL and 
LPLS447X, as compared to no LPL. A two-tailed student’s t-test showed a significant 
difference in VLDL uptake mediated by LPL vs. LPLS447X (p < 0.005). LPL loading is 







Figure 2.8. SPR reveals tighter binding of LPLS447X to LDLR-HIS. 
Binding of LPL (black lines) or LPLS447X (grey lines), at indicated concentrations, to 
immobilized LDLR at was measured in 50 mM Tris 8.0, 400 mM NaCl, 1% glycerol, 
0.005% Tween-20, 2 mg/mL BSA, 2 mM CaCl2, and 1 mM deoxycholate at 25°C. 
Extremely tight binding to both LPL variants was evident by lack of significant 
dissociation, but differences in binding between the two proteins was evident. 
The estimated KD values were 6.16 x 10-10 M and 1.77 x 10-25 M for LPL and LPLS447X, 
respectively; however, these values are only an estimate because the tight binding, 
as evidenced by lack of measurable dissociation, prevents accurate measurement of 







Figure 2.9. Potential Model for the LPLS447X Gain-of-Function. 
A homology model of LPL as predicted by I-TASSER was further refined using 
Rosetta:FloppyTail to find possible C-terminal tail confirmations. A low energy 
structure is shown in which the tail of LPL (439-448 colored in green/blue) occludes 
residues 405-414 (magenta). By this model, residues 447 and 448 (blue) can feasibly 
form hydrogen bonds with residues 411 and 412. Additional Rosetta:FloppyTail 








Figure 2.10. Model of LPLS447X gain of function. 
Removal of two amino acids for LPL’s C-terminus results in improved uptake of 
lipoproteins possibly due to improved access to the known binding site for lipoprotein 
uptake receptors. This model shows wildtype on the left, and the improved access 








Table 2.1. Activity of LPL Variants on DGGR 
 
Vmax KM  
RFU/s M 
LPL (10.82 ± 1.00) x 10-3 (2.78 ± 0.66) x 10-7 
LPLS447X (10.32 ± 1.41) x 10-3 (3.40 ± 0.92) x 10-7 
 
 








TG (M/s) (M) FFA (M/s/mol lipase) 
LPL (5.32  ±  1.37) x 10-4 (6.09  ±  2.82) x 10-3 (4.56 ± 1.45) x 10-2 










CHAPTER 3: SINGLE MOLECULE FLUORESCENCE IMAGING: A NEW 




LPL is a useful therapeutic target not only for LPL deficient individuals, but 
also for the third of the American population that suffers from severe 
hypertriglyceridemia. For many Americans, intervention with available 
pharmaceuticals and lifestyle changes are not sufficient to lower circulating 
triglyceride levels. While Alipogene Tiparvovec is available in Europe for people with 
familial LPL deficiency, no therapies aimed at lowering triglycerides through 
modulating LPL are available outside of clinical trials. 
Improving LPL stability and activity are both attractive targets for use in novel 
therapeutics to improve plasma lipid profiles. Specifically, open research questions 
include how protein inhibitors bind to LPL, how they affect its oligomeric state, and if 
they cooperate to ensure appropriate physiological regulation of LPL’s activity. 
Another major deficiency in the field is a lack of structural information about LPL. 
Resolution of an LPL structure would answer the outstanding question of why LPL 
must be dimeric for activity, and provide a platform for designing therapies aimed at 




A major challenge to using traditional biophysical methods to study LPL 
structure and function is that LPL undergoes extensive post-translational 
modification. LPL is both glycosylated and has ten cysteines that form five disulfide 
bonds. In addition, LPL requires interaction with LMF1, which assists in LPL folding 
within the endoplasmic reticulum(7,26). These requirements limit LPL expression to 
mammalian systems. Unfortunately, the purification from mammalian cell culture 
results in low yields, yet it is the only way to study relevant LPL mutations. 
Additionally, achieving the high protein concentrations of bovine or human LPL 
needed for structural biology, analytical ultracentrifugation, and isothermal titration 
calorimetry is challenging, limiting the use of these technique to understand LPL 
structure-function relationships and LPL’s interaction with regulatory factors. New 
methods to address these questions and to provide a deeper understanding of LPL’s 
function and structure would improve approaches to target LPL with therapeutics.  
Single-molecule techniques provide a novel approach to characterizing LPL 
by exponentially reducing the quantity of LPL necessary to conduct biophysical 
measurements. For example, SPR, which has been extensively used by another 
group to study LPL interactions(99,100), requires several hundred-fold more protein 
per sample than single molecule experiments. We previously used atomic force 
microscopy (AFM) to show LPL and ANGPTL4 binding in a defined complex(53), but 
AFM only provides a snapshot of binding and it cannot provide information on 
dynamics. I thus turned to single molecule total-internal reflection fluorescence 
(smTIRF) microscopy as an alternative approach for measuring LPL/partner binding 




Using smTIRF microscopy, single proteins labeled with a fluorophore can be 
visualized on the surface of a quartz slide(101). smTIRF provides insights into 
protein interactions that cannot be derived from bulk measurements, which provide 
ensemble averages. smTIRF is a well-established technique for studying the 
dynamics of individual protein-DNA interactions(102-105) and protein-protein 
interactions(102). Using smTIRF, real-time measurements of dynamics, occurring in 
individual proteins in response to binding interactions(106), have been observed. 
smTIRF is also particularly useful to identify and measure the lifetimes of different 
complexes and transition states(103), as well as conformational changes(107,108). 
Here, I demonstrate that this technique can be used to study LPL structure-function 
relationships. 
I used fluorescence resonance energy transfer (FRET) to evaluate protein-
protein interactions. In FRET, a donor fluorophore is excited by a single laser. When 
the excited donor fluorophore is close enough to the acceptor fluorophore, non-
radiative energy transfer occurs and the acceptor fluorophore releases lower-energy 
light(109). The energy transfer (E) is dependent on the interfluorophore distance (r) 
and Förster radius (R0), a spectral property of the dyes (See Equation 1). Energy 
transfer therefore can provide an estimate of the distance between the fluorophores. 









The energy exchange that occurs between dyes also provides an internal 




experimental constraints to support computational models of protein structures or 
monitor protein dynamics(110-112).  
In contrast to FRET, colocalization experiments take advantage of tracking 
multiple fluorophores by exciting each fluorophore with a laser and identifying spots 
in which two or more fluorophores are located(113,114). Colocalization is attractive 
for monitoring the binding of fluorescently labeled substrate or an interacting partner 
to a labeled LPL dimer. From such experiments, the stoichiometry and dynamics of 
LPL’s interaction with its regulatory factors can be solved. In colocalization 
experiments the accuracy of measuring complex binding is limited to approximately 
300 nm2(115). Due to non-specific binding to the slide, internal controls for 
colocalization experiments are extremely important.  
The application of these two single molecule fluorescence approaches to 
study LPL has great potential to impact the field of LPL biology. Without single 
molecule techniques, LPL studies will continue to be limited by protein concentration 
and yield. A major obstacle for conducting single-molecule fluorescence experiments 
is developing the conditions for protein labeling and attachment to slides without 
affecting the activity of the protein(101). I established methods to begin 
characterizing LPL interactions and dynamics using these techniques and apply 
them to outstanding questions in the field. Methods of data collection and analysis 







Materials and Methods 
Molecular Cloning 
LPL variants were cloned into pCDNA5/FRT/IRES (ThermoFisher Scientific) 
with the addition of either a 6x polyhistidine-tag or a V5 tag (GKPIPNPLLGLDST) on 
the c-terminus. Lmf1 was included in the plasmid to improve LPL folding and secretion. 
Single cysteines at positions S12, S36, S63, S97, S193, V224, S240, S251, S259, 
S323, S346, and S384 were introduced using Quickchange site directed mutagenesis. 
A single cysteine-containing variant of ANGPTL4 was generated by making C76A, 
C80A mutations in pET16B_ANGPTL4(53). Next, residue A160 of ANGPTL4 was 
mutated to a cysteine, to provide site-specific modification by a fluorophore.  
 
LPL Protein Expression and Purification 
LPL was transiently or stably transfected into HEK 293 FRT Flip-In cells 
(ThermoFisher Scientific) using Fugene 6. Expression and purification of LPL was 
carried out as previously described(120). Washing with ≥ 75 column volumes was 
necessary to eliminate cleavage products. Protein was concentrated, aliquoted, flash 
frozen in liquid nitrogen, and stored at -80 °C until use or immediately labeled.  
 
Preparation of Fluorescent Cysteine Labeled LPL 
Single cysteine mutants of LPL were purified and incubated with an 
approximately ten-fold molar excess of Alexa Fluor® Maleimide Dyes (Invitrogen). 
Label was added dropwise to the protein solution followed by gentle mixing. The 




ice. LPL was then diluted 70% with 20 mM Bis-Tris pH 6.5 and re-purified over a 
HiTrap Heparin Sepharose High Performance Column (GE Healthcare Life Sciences) 
to remove excess label. Excess label flowed through the heparin column whereas 
purified, labeled LPL bound and eluted normally. Alternatively, the label could be 
removed by use of two tandem 7 kDa Zebra desalting columns (ThermoFisher 
Scientific). LPL samples were aliquoted and stored at -80 °C until use. Samples 
purified from spin columns were syringe filtered through a 0.2 μm PDVF filter to 
remove aggregates. 
 
Preparation of Active-Site Fluorescent Labeled and Biotinylated LPL 
To label LPL’s active site, LPL was incubated for 30 minutes, on ice, with ActivX 
TAMRA-FP Serine Hydrolase Probe (ThermoFisher Scientific). Next, a 1-2 molar 
excess of Biotin-N-Hydroxysuccinimide ester (Sigma) was added and the reaction was 
allowed to proceed on ice for another 10 minutes. LPL was re-purified over a HiTrap 
Heparin Sepharose High Performance Column (GE Healthcare Life Sciences) to 
remove excess probe and biotin. Protein could also be desalted using two tandem 7 
kDa Zebra desalting columns (ThermoFisher Scientific). LPL samples were aliquoted 
and stored at -80 °C until use.  
 
Activity of LPL on a Surface 
A 96-well black-sided, clear-bottom plate was functionalized by brief incubation 
with biotinylated bovine serum albumin (Sigma, 1 mg/ml, 5 minutes), three washes 




with PBS. The plates sat on ice with PBS in the wells until the experiment was ready 
to proceed. Wells were then treated as follows: A) No LPL (Buffer), B) biotinylated 
bovine LPL (~150 nM, 5 minute incubation), C) Heparin-Biotin (Sigma, 1 mg/ml, 5 
minutes) + bovine LPL (150 nM, 5 minutes). Wells were washed three more times with 
PBS and substrate was added (150 mM NaCl, 0.4% Triton-X, 20 mM Tris 8.0, 14 µM 
DGGR). Wells were excited at 529 nm with a 590 nm cut-off and read for emission at 
600 nm on a SpectaMax 5 plate reader. 
 
Activity of Fluorescently Labeled LPL 
Purified LPLS384C was modified as described above with Alexa Fluor®647 dye 
and desalted through a 7 kDa Zebra desalting column (ThermoFisher Scientific). The 
protein was then quantified. The activity of equal concentrations of labeled and 
unlabeled LPLS384C was measured as previously described(53), with the addition of 1 
mM deoxycholate. 
 
Single Molecule TIRF Microscopy Slide Preparation 
Home-built flow cells on quartz slides were prepared as previously 
described(119). The surface of the slides was pre-functionalized by brief incubation 
with biotinylated bovine serum albumin (Sigma, 1 mg/ml, 5 minutes), washing, and 
followed by incubating with streptavidin (Invitrogen, 0.1 mg/ml, 20 minutes) and 
washing. For slides utilizing heparin attachment, biotin-heparin (Sigma, 1 mg/ml, 5-10 
minutes) was also added directly to the slides. Immediately preceding data collection, 




approximately 5 minutes. Experiments were carried out in Buffer A (50 mM Tris, 100 
mM sodium acetate, pH 7.8). 
Unbound LPL was then washed out with Buffer A. Imaging buffer was then 
added to the slides (Imaging Buffer = Buffer A plus an oxygen scavenging system (2% 
glucose (Sigma), 1% β-mercaptoethanol (Sigma), 0.1 mg/mL glucose oxidase 
(Sigma), and 0.025 mg/mL catalase (Sigma)) to prolong the fluorophore lifetime and 
a triplet state quencher (∼50 μM cyclooctatetraene (Sigma)) to lessen fluorophore 
blinking.) 
 
TIRF Microscopy Imaging 
The slides were imaged using a through-prism TIRF laser microscope. 
Fluorophore excitation was achieved using constant illumination with 532 nm and 638 
nm lasers. The fluorophore emissions were collected through a 60X water immersion 
1.2 N.A. objective, and the image was split using a DualView optical splitter (Chroma) 
equipped with a 645 nm dichroic mirror. The emission signals passed through optical 
filters before detection with a Cascade 512 (Photometrics) emCCD camera: a 585/70 
bandpass filter (Chroma) for the TAMRA/Alexa Fluor®555 emissions and a 655 nm 
longpass filter (Chroma) for the Alexa Fluor®647 emissions were used. Movies of 
approximately 110 seconds in length were collected at a 100 ms frame rate, using 







LPL-LPL Interactions Visualized by TIRF Microscopy 
Experiments were carried out as described above using the biotin-heparin 
mode of attachment, and a “Buffer A” containing 50 mM Tris, 300 mM sodium chloride, 
5 % glycerol, 1 mM deoxycholate, pH 7.5. LPL molecules were fluorescently labeled, 
as described above, at specific cysteine residues and mixed together immediately 
preceding imaging. Residual LPL was then washed off the slides. For the experiments 
shown, buffer with only cyclooctatetraene or no oxygen scavengers was used to 
promote fluorophore bleaching. During image capture, only the red (acceptor) laser 
was turned on for the first 10 frames and again after the 1000th frame. From frames 
10-1000, only the green laser was turned on to visualize FRET. 
 
Single Molecule TIRF Data Analysis 
The fluorescence intensities of single molecules were extracted from the 
movies using in house software, as previously described(121). Traces were analyzed 
only if LPL fluorescence intensity was present at the start of the movie. Time traces 
with intensities above or below threshold intensities (empirically determined) for single 
molecules were excluded from further analysis. The remaining intensity traces were 
then smoothed using a non-linear Chung-Kennedy filter that preserves 
edges(122,123).  
LPL-LPL interactions were analyzed and the average FRET values of the 
bound complex were calculated. ANGPTL4 binding events were observed as brief 
periods of Alexa Fluor®647 emission. Two automated methods to detected changes 




previously(103), and ii) a method using the point-by-point standard deviations from 
the Chung-Kennedy filter. For ANGPTL4 binding to LPL, the transitions were then 
used to calculate dwell times of the binding events. Hundreds of dwell times were 
collected, and KaleidaGraph was used to fit each data set to the equation for single-
exponential decay (y = y0*e-kt). To compare dwell times from different protein variants, 
a half-time for each variant was calculated (t1/2 = -ln(1/2)/k ). Standard error is reported. 
 
Part 1: Developing Methods LPL for Single Molecule Fluorescence 
Attachment of Active LPL to Slides for Single Molecule Fluorescence Studies 
 Single molecule TIRF microscopy allows for the visualization of single 
molecules within ~200 nm of the surface of the slide. To monitor a molecule over time, 
it is necessary to attach the complex to the surface. There are various methods for 
attaching macromolecules to slides, such as protein-specific binding reagents, 
antibodies, liposomes, and biotin linkages. The former methods could all be applied 
to LPL studies, except for liposomes. Liposomes circumvent the need to use protein 
linkages to attach proteins to slides, but would not be strategic to use with an active 
lipase. Attaching molecules to slides ensures that they can be monitored over the 
course of an experiment. Further, using affinity methods for attachment has the 
advantage that it can help position molecules in the same orientation, with respect to 
the slide, and provides control over protein deposition.  
I devised two approaches, using biotinylated bovine serum albumin (BSA) 
bound to streptavidin, to attach LPL to slides. BSA blocks nonspecific binding of target 




conjugates on the surface of the slides. In one approach, I took advantage of LPL’s 
strong affinity for heparin, and utilized biotin-conjugated heparin to bridge LPL to 
functionalized slides (Figure 3.1A, right panel). Heparin binds to LPL’s C-terminus, 
and has been shown to stabilize LPL against inactivation(124). BSA conjugated 
directly to heparin is available, but is more expensive than the strategy that I used. In 
the second approach, I used LPL that was directly biotinylated and then allowed to 
bind to a BSA-biotin-strepavidin functionalized slide (Figure 3.1A, left panel). 
Biotinylation of LPL provides a method that may be particularly useful for monitoring 
LPL interactions that utilize LPL’s heparin binding site.  
I showed that both biotinylated LPL and the heparin-biotin conjugate were 
suitable methods for attaching active LPL to slides (Figure 3.1B); however, because 
the biotin ester can covalently react with any available amine, I found that excessive 
biotinylation of LPL reduces its activity, thus using a very small molar excess of biotin 
to modify LPL, along with a short incubation period, is necessary to maintain low-
labelled, active protein, as shown (Figure 3.1B). The heparin-biotin conjugation does 
not have this undesirable effect. In fact, heparin is known to stabilize LPL and 
represents a more physiological mode of attachment(124). Accordingly, I used the 
heparin method for monitoring LPL-LPL interactions and the biotin approach when 
monitoring binding interactions that may require LPL’s heparin binding site. Notably, 







Two Methods for Specific Labeling of LPL with Fluorophores 
After establishing methods to attach LPL to slides, I determined methods for 
attaching fluorophores at different, specific locations on LPL. I used two methods for 
specifically labeling LPL (Figure 3.2A). In the first method, I used maleimide 
fluorophores that react with free cysteines. I took advantage of the fact that although 
LPL contains ten cysteine residues, they are incorporated into five critical disulfide 
bonds, leaving no native cysteines available for labeling. Therefore, I engineered 
specific labeling sites by introducing additional cysteines. I added an additional 
cysteine residue either on the lid that covers the active site or elsewhere on LPL 
(Figure 3.2A, top cartoon). To add non-lid cysteine residues, I chose to mutate 
serines to minimize potential structural and functional changes. I mapped LPL’s 40 
serine residues on a computational model of LPL to identify serine residues in 
distinct regions (near the lid, C-terminus, N-terminus, see Figure 3.2A, B). All serine 
to cysteine mutants, except LPLS251C, are secreted, and several exhibit activities 
similar to wild-type LPL (Figure 3.2C). As expected, LPL with an introduced cysteine 
are readily labeled with the maleimide dye Alexa Fluor®647, whereas wild-type LPL 
is not labeled under the same conditions (Figure 3.2D, top panel). In addition, I show 
that maleimide labeling does not hinder the activity of one of the purified cysteine 
mutants, LPLS384C (Figure 3.2E).  
Another method that can be used to label LPL is an activity-based protein 
profiling (ABPP) probe, ActivX™ TAMRA-FP serine hydrolase probe, which readily 
labels LPL’s active site (Figure 3.2A, bottom image). This labeling method is well 




such as studies that measure protein-protein interactions. A huge advantage of using 
ABPP is that it is possible to label active LPL from any source. The commercially 
available serine hydrolase probe is conjugated to a TAMRA fluorophore, which is 
compatible with our single molecule approach. Unfortunately, this probe does bind to 
serum in media, and thus purified LPL should be used. Purified LPL labeled with the 
serine hydrolase probe is shown in Figure 3.2D, middle panel. A Western blot against 
LPL, showing total LPL protein, reveals a similar amount of active LPL between the 
two samples (Figure 3.2D, bottom blot). Finally, because fluorophores are prone to 
bleaching, I confirmed that LPL remains active in buffers containing oxygen 
scavengers (Figure 3.3). 
Site-specific labeling is particularly important for FRET studies because FRET 
requires the donor and acceptor dyes to be sufficiently close together and FRET 
distance measurements depend on the specific locations. It has been previously 
shown that LPL is a homodimer in which the subunits undergo rapid exchange(21). 
To measure FRET within the LPL dimer, this rapid exchange allows for two different 
specifically labeled LPL dimers to be mixed to form LPL dimers containing both 
fluorophores. To use FRET to measure the interaction of LPL with itself or other 
proteins, LPL can be labeled with one fluorophore and mixed with a differently 








Part 2: Visualization of LPL Interactions Using TIRF 
Visualizing LPL-ANGPTL4 Interactions Using Colocalization Experiments 
Colocalization experiments are particularly powerful for measuring complexes 
with multiple molecules or proteins (113,114,125). To identify colocalized proteins, 
both lasers are turned on and the proteins are simultaneously monitored over time for 
overlap in one spot. The Neher and Erie Labs previously used AFM to show the 
stoichiometry of LPL:ANGPTL4 binding(53). AFM is unable to provide information on 
protein dynamics. I thus used colocalization experiments to analyze ANGPTL4 binding 
to human LPL. In these assays, LPL’s active site was labeled using the ActivX™ 
TAMRA-FP, and then labeled LPL was treated with biotin to facilitate its attachment 
to a quartz slides for imaging. To label ANGPTL4, I generated an ANGPTL4 variant 
with a single cysteine at position 160 (see methods). This variant was labeled with 
maleimide-conjugated Alexa Fluor®647, and the fluorophore-labeled variant was still 
able to inhibit LPL (Figure 3.4). In these experiments (Figure 3.5A), biotinylated LPL 
was immobilized on the slide, ANGPTL4 was manually flowed over the slide, and 
binding to LPL was observed.  
Figure 3.5B shows an example trace of an LPL dimer (light grey trace) 
comprised of two fluorescently labeled monomers bound to the slide. Inspection of 
these data shows that the dimer remains bound, as seen by constant fluorescence 
intensity of ~700, until 70-80 seconds. From 70-80 seconds, one of the two 
fluorophores on the LPL dimer blinks twice, as seen by two brief 50% decreases in 
fluorescence intensity. Subsequently, both LPL fluorophores bleach at 80 seconds as 




(black trace) is seen until ~18 seconds when a brief increase in fluorescence occurs, 
followed by the return of the signal to zero. This increase in fluorescence is a result of 
ANGPTL4 binding. From this trace, the length of time ANGPTL4 is bound to LPL (dwell 
time) is determine from the length of time the ANGPTL4 fluorescence signal is present. 
The lifetime of ANGPTL4 binding to LPL is determined by plotting a histogram of the 
dwell times measured from hundreds of similar events (N = 322), as seen in Figure 
3.5C, and fitting the data to the equation for single-exponential decay(126). The half-
life of ANGPTL4 bound to LPL is 3.7 ± 0.2 seconds. By contrast, non-specific binding 
of ANGPLT4 to the slide (data not shown) occurs with a half-life of ~1 second.  
In addition to monitoring the binding dynamics, this experimental setup can also 
be used to calculate stoichiometries of binding complexes or visualize events where 
an inhibitor dissociates the LPL dimer. In this example, ANGPTL4 simply binds to and 
dissociates from LPL. ANGPTL4 does not promote the dissociation of one of the 
monomers of LPL in this case because dissociation of a monomer would result in 50% 
decrease in fluorescence in the LPL trace when ANGPTL4 dissociated. We did 
observe two LPL blinking events from ~70-80 seconds, in which half of the LPL signal 
was lost and then quickly returned, but they occurred much later than ANGPTL4 
binding. We then observed an LPL bleaching or dissociation event, in which all of the 
LPL signal was lost at ~80 seconds. Together, the distinct and equal blinking and 







Use of Intermolecular FRET to Measure LPL Dimer Dynamics and Structure 
Another approach to monitoring protein interactions is FRET. FRET values can 
be used to estimate the distances between dyes (116,117). Each FRET fluorophore 
pair has a given distance, R0, at which half of the energy is transferred. For the 
fluorophores used here (Alexa Fluor®555 and 647), the calculated R0 distance is 
approximately 51 angstroms. This distance can vary slightly depending on the 
orientation of the fluorophores and their environment, but use of the same dye pair 
within a complex allows the measurements to be analyzed relative to one another. 
The number of interactions that can be monitored simultaneously via FRET is 
limited by the number of fluorophores that can be tracked, which is limited by the 
spectral properties of the fluorophores. Previous reports have used up to four dyes for 
FRET(102,127-129). We found that LPL is well suited for FRET studies as each 
monomer can be labeled with a different fluorophore and mixed, resulting in a dimer 
that undergoes FRET.  
To generate distance constraints for a model of LPL’s structure, hundreds of 
individual FRET measurements, for multiple sets of LPL mutants, could be collected 
and plotted as a population in a histogram. Based on a Gaussian fit, an average FRET 
value (and distance) for each mutant pair is then calculated. FRET distances from 
many combinations of LPL cysteine mutants can be used to constrain a computational 
dimer model. Measuring distances between LPL dimer partners using a single 
molecule approach has the distinct advantage of allowing selection of only those 
complexes with one donor and one acceptor for analysis. Notably, if these 




populations with no acceptor would give off high donor fluorescence and thus reduce 
the apparent FRET.  
To monitor FRET, an automatic alternating laser system was used to toggle 
lasers (see methods). Time traces for individual molecules were extracted and 
analyzed. Traces were then manually sorted and only FRET events that involved one 
acceptor and one donor, as evidenced by single step changes in intensity to zero from 
blinking or bleaching events, were analyzed.   
Example FRET data are shown in Figure 3.6. An in-depth discussion of the 
analysis methods can be found in previous literature (106,130). We explain these 
examples, and apply the experiments towards resolving a more-accurate LPL 
structural model. In Figure 3.6A, structural depictions for each set of mutants are 
provided. Panel 1 shows the LPL dimer composed of two monomers where the  
cysteine mutant is introduced into LPL’s lid (LPLV224C). Each subunit of the mutant is 
labeled with maleimide-conjugated Alexa Fluor®555 (donor, green) or Alexa 
Fluor®647 (acceptor, red). In the second panel, LPLV224C*green was combined with 
LPLS259C*red. LPLS384C*red is combined with LPLS384C*green in the third panel and  
LPLS36C*green in the final panel. Labeled monomers were mixed and attached to slides 
functionalized using the biotin-heparin method we describe above.  
Inspection of the traces shown in Figure 3.6B reveals changes in red and green 
fluorescence first as the green laser switches on (at approximately 1.5 seconds in all 
the traces) and then as the donor (green) fluorophore bleaches before the end of each 
trace. The FRET values shown in the lower panel, Figure 3C, were calculated using 




Throughout the course of the fluorescence traces some small anticorrelated changes 
can be observed, suggesting small-scale protein movements. Other conformational 
changes also occur, suggesting the protein changes states. In Figure 3C, panel 1, 
there is a small but steady decrease in FRET from approximately 4.5 seconds until 
the donor bleaches. Although it is possible that the donor LPL dissociated and was 
replaced by a different, unlabeled, molecule, the loss of green fluorescence in panel 
1 is most likely a bleach because the intensity goes to zero without many small 
changes in FRET. In the second panel, which shows LPLV224C*green combined with 
LPLS259C*red, several small changes in FRET can be observed before the acceptor 
vanishes, suggesting a conformational change as the acceptor labelled monomer 
leaves. Shortly after the LPLS259C*red leaves, the donor also bleaches.  
The fluorescence and FRET for panel 3 is rather unremarkable, but panel 4 is 
much more interesting. In panel 4, LPLS384C*red and LPLS36C*green are on the surface 
and start at a high FRET state near 1.0. At approximately 3 seconds, a conformational 
change occurs that results in a rapid decrease, but not loss, in the FRET. From there, 
an additional conformational change occurs in which the FRET slightly increases, at 
approximately 6.5 seconds.  
Data for hundreds of molecules undergoing FRET was analyzed and individual 
protein states were identified. For each state, a representative sample of 10 FRET 
points was taken, pooled with the rest of the data for that mutant, appropriately binned, 
and plotted in a histogram representing the entire population (Figure 3.6D, all panels). 




mean FRET value(s). These values were then converted into distance measurements 
using Equation 1 from earlier in this chapter. 
In Figure 3D, panel 1, the FRET efficiency from one LPLV224C to the next was 
found to be 0.62 which is an estimated distance of 47 angstroms. In our final histogram, 
the two states seen in the trace are not obvious, probably because they are quite 
popular and near the R0, which is the most sensitive region.  
As shown in panel 2, the histogram for LPLV224C to LPLS259C reveals one major 
population at 0.81, with secondary states around 0.43 and 0.67. These distances 
correspond to 40, 45, and 53 angstroms, respectively. Likewise, the histograms for 
FRET efficiency between LPLS384C and LPLS384C or LPLS36C show one major and one 
minor peak, indicating that at least one labelled mutant position adopts two 
conformational states. The populations had FRET values of 0.43 and 0.88 for the 
mutant with itself and 0.52 and 0.82 for LPLS384C with LPLS36C. These values 
correspond to estimated distances of 53, 37, 50, and 40. These similar populations 
suggest that the dimers may be approximately halfway offset to one another. We used 
distances derived from the most prevalent state for modeling. 
 
Initial Modeling of LPL Dimers 
Although structural models of LPL exist, current models are only 
computationally derived(131). In particular, little is known about the LPL dimer 
orientation and no true structural models of the dimer exist. Adding FRET-generated 
distance constraints would enhance structural models. Studies support the 




docked remains a mystery. Mike Lafferty in the lab undertook studies of LPL 
modeling. First, he used HADDOCK (132) to dock the LPL dimer. The results of the 
docking suggested three possible head-to-tail conformations (Figure 3.7). Figure 
3.7A shows a model in which the lids are buried next to each other within the dimer 
interface. Figure 3.7B is where the lids are still next to one another, but less buried in 
the interface. The model in Figure 3.7C positions the lids near the lipoprotein binding 
site on the opposite protein’s C-terminus.  
This final model makes the most scientific sense in that the lids likely would 
not clash when they open. Based on previous studies aimed at modeling LPL, it is 
known that the active sites use the opposite dimer’s lipoprotein binding region, on 
the C-terminus, for long-chain substrate binding. When the three tryptophan 
residues, responsible for long chain substrate binding are mutated, the opposite LPL 
molecule can only hydrolyze short chain substrates (24). 
When we looked at the FRET derived distances and compare them to the 
predicted distances from the HADDOCK models, the experimental data did not 
support the models. For the third model, the modeled distances were 34 angstroms 
for the LPLV224C positions, 25 angstroms for the LPLV224C LPLS259C, 34 for LPLS384C to 
itself and 42 angstroms for LPLS384C to LPLS36C. This model, with the mutations 
labelled, is shown in Figure 3.8. These distances are shorter than the experimentally 







Rosetta Was Used to Generate Refined Models 
Mike used Rosetta to produce more refined dimer models. Mike input an LPL 
monomer and let Rosetta dock the dimer into the most energetically favorable 
positions using either rigid or global docking. In rigid docking, the individual 
monomer backbones are kept rigid, but whole-monomer and sides chain movements 
are allowed while in global docking, the monomers can undergo larger 
conformational changes to adjust to a more energetically favorable position. 
Several of the best resulting models are shown in Figure 3.9 A-F. Models A 
and B are renditions of the third HADDOCK model, but the dimer is much more 
condensed and the dimers less offset. Models A and B both had distances closer the 
experimental data, except for the pair LPLS384C and LPLS36C, which had a shorter 
predicted distance than my data suggests. A model somewhere between the third 
HADDOCK model and these models would likely be the best fit for a head-to-tail 
confirmation. 
Models C and D have the lids quite near one another, instead of near the 
substrate binding site. Using the distances generated from Figure 3.6, I eliminated 
models C and D, which had LPLV224C - LPLV224C measurements of 30 and 10 
angstroms, respectively, which does not fit the experimental data well. Finally, 
Models E and F were odd models that had mostly favorable distances, but they do 
not fit the expected head-to-tail conformation despite their distances being a good fit 
for the data. While these models seem an unlikely fit, it’s possible that a model that 





Conclusions and Future Applications of This Method 
Here, I describe a single molecule method for measuring LPL interactions 
through the use of suitable cysteine mutants, labeling strategies, and modes of 
attaching LPL to slides. I show that fluorophore colocalization is an effective tool to 
measure the binding of fluorescently labeled LPL regulatory factors, such as 
ANGPTL4 at a level of detail that cannot be observed through bulk methods. 
Further, this technique proved effective at monitoring LPL-LPL interactions. Based 
on the models generated using HADDOCK and Rossetta, two similar models were 
generated, each with slight variation from the experimental data. To resolve this 
issue, future studies modelling these structures with the addition of dyes will be 
conducted to evaluate the best structural model.  
In the future, this method will be harnessed to monitor the binding of 
additional LPL regulatory factors to LPL and monitor changes in LPL’s conformation 
upon binding of a lipid substrate. This is important because how LPL accesses the 






Figure 3.1. Active LPL Can be Attached to a Slide Using Two Methods. 
A) Quartz slides can be functionalized for LPL attachment with BSA-biotin, 
streptavidin. LPL is then attached either after being conjugated to biotin (left) or after 
the addition of biotinylated heparin (133) to the slide. LPL avidly binds to heparin.  
B) LPL remains active on a functionalized surface. LPL was bound to a BSA-biotin-
streptavidin coated 96-well plate. The activity of the LPL remaining in the wells after 
washing was read after the addition of a substrate mixture containing DGGR. Both 
biotinylated LPL and LPL bound to the surface after functionalization with heparin-








Figure 3.2. Strategies for Fluorescently Labeling LPL. 
A) LPL can be labeled specifically using maleimide dyes or covalently in the active 
site using a serine-hydrolase probe.  
B) Serine residues on LPL are labeled in red, on a previously described LPL 
model(60). 
C) LPL cysteine mutants with a V5 tag were transiently expressed and the media 
was tested for activity, representative data is shown. Secreted (media) and lysate 
fractions are shown, probed against the V5-tag. A GAPDH loading control for the 
lysate is shown. The standard deviation of triplicate wells is shown.  
D) Wildtype LPL or an LPLS97C with a V5 tag, were labeled concurrently with Alexa 
Fluor®647 and ActivX-Serine-Hydrolase and then run on a gel and visualized for 
fluorescence. A western blot against LPL (third panel, ⍺ 4-1a) shows total protein.  
E) LPLS384C retains activity when labeled with Alexa Fluor®647 maleimide dye 






Figure 3.3. LPL Maintains Activity in Oxygen Scavenging Buffers.  
5 nM LPL was assayed for activity in the different oxygen scavenging buffers used 
for imaging, cyclooctatetraene (50 µM), catalase buffer (2% glucose, 1% β-
mercaptoethanol, 0.1 mg/mL glucose oxidase, 0.025 mg/mL catalase, and 50 μM 
cyclooctatetraene), or β-mercaptoethanol (1%). The fluorescent substrate EnzChek 
(10 µM) was used as previously reported(134) as reducing agents disrupt DGGR 
measurement. Some loss of LPL activity was seen for buffers containing βME 
(catalase buffer and βME), but it could be due to disruption of the assay substrate as 








Figure 3.4. ANGPTL4 Labelled with a Fluorophore Can Still Inhibit LPL. 
LPL (5 nM) was assayed using DGGR in the absence or presence of an equal 
amount of wildtype, mutant, or labelled mutant ANGPTL4. Both labelled and 
unlabeled mutant ANGPTL4 were equally potent LPL inhibitors, compared with 








Figure 3.5: Single Molecule Binding of ANGPTL4 to LPL.  
A) Labeled LPL is attached to a slide for TIRF imaging. Labeled ANGPTL4 is flowed 
into the slide, and ANGPTL4-LPL interactions are measured.  
B) An example trace showing ANGPTL4 (black trace) binding to LPL (light grey 
trace).  
C) Distribution of the dwell times of ANGPTL4 binding to LPL (N = 322) was fit to the 
equation for single-exponential decay, then the half-life of ANGPTL4 bound to LPL 







Figure 3.6. Examples of LPL-LPL Intermolecular FRET. 
A) Cartoons of LPL dimer mutants, labelled with their respective fluorophores. Green stars 
represent a donor labelled partner while red represents the acceptor fluorophore attached to 
the appropriate LPL mutant. The black bar connects the two, showing a relative distance. 
B) Example time traces showing dimers bound to the surface and undergoing FRET. As the 
green laser automatically turns on, fluorescence is observed just before the 2 second mark 
in each trace. In each case, the green fluorophore vanishes before the end of the trace, 
marking the donor bleach. In the second panel, the acceptor bleaches first. 
C) FRET traces for the fluorescence traces shown in part B are given. In all four panels, the 
FRET returns to zero when a fluorophore bleaches.  
D) Extracted FRET values were plotted as histogram distributions for each mutant. For 
V224C-V224C, traces from 46 molecules were analyzed. A major population of the FRET 
efficiency of V224C-V224C is found around 0.62. Traces from 56 molecules, were plotted 
for V224C-S259C. For this pair, several states are observed with the largest fraction near 
0.81. In the third panel data from 37 traces of S384C-S384C were plotted and the Gaussian 
fit of the FRET efficiency was 0.42 while many the molecules were binned at 0.51. As with 
the next panel, there is another population present with high FRET. The final panel shows 
data from 33 molecules of S384C with S36C. Three distinct states are observed, all of which 








Figure 3.7. LPL Dimer Models Generated by HADDOCK. 
The HADDOCK server was used to model docking of LPL as a dimer. Each monomer 
of LPL is shown as either blue or green, and LPL’s lid is shown in black. The three 






Figure 3.8 LPL Dimer Model Labelled with Appropriate Dye Positions. 
The third HADDOCK model from Figure 3.7 is shown here with appropriately labelled 
dye positions. While the measured distances were rather short, the relative distances 
for the S384C paired donors appears to be consistent with our data. In addition, the 
relative distances between V224C and its partners also appears consistent with our 







Figure 3.9. A Sample of LPL Dimers Docked Using Rosetta. 
Rosetta was used to generated models using rigid body or global docking. A selection 
of representative models of the top energetically favorable confirmations are shown. 
Models A and B resemble two dimers with their lids near the lipoprotein/long-chain 
substrate binding patch. Models C and D show a model where the lids are close to 
one another and might potentially clash. Models E and F show two models that were 







CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
 
 LPL is a critical enzyme in the hydrolysis and breakdown of TRLs. It is the 
best studied of the three dimeric lipases in its family, yet much remains to be 
understood about the function of this enzymes and why the three dimeric family 
members require homodimerization for activity while most human lipases are active 
as monomers. When I began undertaking the research presented here, few labs 
readily studied purified human LPL in vitro, opting for the more stable, cheaper to 
purify, bovine LPL or relying on unpurified LPL in tissue culture media, which 
contains mostly inactive full-length and cleaved protein. Purification of human LPL is 
a time and resource intensive undertaking, but I have shown here the importance of 
using the purified enzyme to accurately measure LPL function.  
The work presented here highlights my published and ongoing studies to 1) 
provide a better understanding of ways to improve LPL function, 2) develop a 
method to better study human LPL interactions, and 3) provide an experimentally 









Improvements in Our Understanding of LPL as a Therapeutic Target 
LPLS447X Study Suggest Lipoprotein Uptake is More Important Than TRL Hydrolysis 
in Individuals with Functional LPL. 
 My finding that LPLS447X promotes lipoprotein uptake better than wildtype is 
strongly supported by in vivo data showing that LPLS447X carriers have improved 
triglyceride rich particle clearance(84,96,135). It makes sense that clearance of a 
partially hydrolyzed triglyceride rich particle from circulation would have a stronger 
impact on triglyceride levels than hydrolysis of more triglycerides alone as lipoprotein 
particles contain high concentrations of triglycerides.  
Lipoprotein uptake has long been an aim of cholesterol lowering drugs, which 
often target lipoprotein receptors. For example, studies of individuals with excellent 
cholesterol levels found that carrying a loss-of-function mutation in proprotein 
convertase subtilisin/kexin type 9 (PCSK9) was cardio protective(136,137). PCSK9 
is a protease that helps target LDLR for lysosomal degradation. Loss of PCSK9 
function allows for more LDLR to reach the surface of the liver, thus promoting more 
LDL uptake and leading to an overall decrease in circulating LDL levels. This recent 
finding led to a rush for the development of drugs aimed at downregulating PCSK9 
in an effort to improve cholesterol levels. Two medications are already available, 
alirocumab and evolocumab(138,139). Others are rushing to produce more drugs 
with the same affect using antibodies(140), vaccines(141,142), and in vivo gene 




In fact, my lipoprotein uptake hypothesis was prompted by population studies 
in which it was often found that women, who often have lower triglycerides on 
average, do not often have the same benefit from carrying the mutation as men(72). 
Women’s lower circulating triglycerides could be due to estrogen’s ability to 
upregulate LDLR production, perhaps through regulation by PCSK9(144). Due to 
side effects, estrogen therapy would not be a good treatment for 
hypertriglyceridemia, but the contrasting difference between men and women does 
highlight how upregulation of lipoprotein uptake receptors are a suitable and 
reasonable approach to treating people suffering from hypertriglyceridemia. 
Another implication of the work I presented above is that lipoprotein uptake 
alone may be a useful treatment for people with properly functioning LPL, but 
elevated triglycerides. Patents are already in place for LPL enzyme replacement 
therapy; however, such therapies will be challenged by the poor yield and stability of 
human LPL. In contrast to full-length LPL, LPL’s C-terminus can be purified from 
E.coli and is capable of promoting lipoprotein uptake(98). While conducting my 
lipoprotein uptake assays, I used bovine LPL as a positive control and found that I 
needed 10-20 fold more bovine LPL to promote approximately equal lipoprotein 
uptake compared to the minimal levels of human LPL necessary. This highlights the 
importance of using human LPL for enzyme replacement, and it also suggests a 







LPL Regulation by ANGPTL4 and GPIHBP1  
  There are conflicting reports about how ANGPLT4 and GPIHBP1 compete 
for LPL binding. My data contributes to resolving this conflict. One group has shown 
that GPIHBP1 can protect LPL from ANGPTL4 inhibition(57) while another found 
that ANGPTL4 strips LPL from GPIHBP1 anchors on cells(58). Although these 
studies differ in that the former used purified proteins in vitro and the latter uses cells 
in culture, my data supports the later work by Brandon Davies’ lab that suggests 
GPIHBP1 does not protect LPL from ANGPTL4 inhibition.  
My hypothesis is that ANGPTL4 has two mechanisms that result in LPL 
inhibition. First, ANGPTL4 briefly binds to LPL during which it inhibits substrate 
hydrolysis. Second, when ANGPTL4 binds to LPL, it also knocks off stabilizers, such 
as GPIHBP1 or deoxycholate. This removal of stabilizers leaves LPL “naked and 
alone” and susceptible to heat inactivation after ANGPTL4 dissociation. 
Our group previously showed that ANGPTL4 is a reversible LPL inhibitor(53), 
but controversy remains over the inclusion of deoxycholate, a bile acid, in these 
assays. In my hands, human and bovine LPL have a similar Ki for ANGPTL4 
inhibition, when assayed in the presence of deoxycholate. When I assay low 
concentrations of human LPL in the absence of stabilizers, like deoxycholate (a 
naturally occurring bile salt) or GPIHBP1, the LPL rapidly inactivates in the absence 
of ANGPTL4. In the presence of stabilizers, which likely represents a more 
physiological situation, LPL is fairly resistant to heat inactivation, but still inactivates 
in the presence of ANGPTL4.  My unpublished data has shown me that bovine LPL 




may be best explained by their production. Bovine LPL is purified from cow’s milk, 
which is rich in small molecules potentially capable of stabilizing LPL, while human 
LPL is purified from low-serum tissue culture media. Further studies will be 
necessary to identify the small molecule(s) that bind and stabilize LPL milk and 
plasma.  
 
Single Molecule Experiments Provide a New Avenue for Understanding LPL 
 While lipoprotein uptake is presumably a starting point for helping individuals 
suffering from elevated triglyceride rich lipoproteins, my study shows how important 
in vitro biochemistry is in answering fundamental biological challenges. Many of the 
outstanding questions in the LPL field remain biochemical questions as LPL cannot 
be assayed using most traditional biophysical measurements. When I turned to a 
single molecule approach to studying LPL, I welcomed a method that would allow us 
to see not only how individual LPL molecules responded to different stimuli, but also 
generate distance constraints for a better LPL model. 
 
ANGPTL4 Binding to LPL is Short-lived. 
As emphasized throughout this thesis, LPL is a highly regulated enzyme, yet 
little is known about how its factors bind and alter LPL’s function. We know little 
about where proteins interact with LPL, their stoichiometry, and how they alter LPL’s 
structure or function. I decided to study an interaction our lab has been intensely 
interested in, LPL-ANGPTL4. I found that the half life of ANGPLT4 on LPL was fairly 




ANGPTL4, at least in vitro, is fast enough that a therapeutic against ANGPTL4 might 
not need to be able to displace ANGPTL4 from LPL, but instead just bind free 
ANGPTL4 and prevent its rebinding to LPL molecules. A fast interaction time also 
suggests that if my hypothesis from above about ANGPTL4 leaving LPL “naked and 
alone” is true, then it is equally important to focus therapeutics on stabilizing LPL 
instead of reducing inhibition of LPL by ANGPTL4. 
  
  
FRETting Over a Better LPL Dimer Model 
 A major challenge to understanding LPL and designing therapeutics to 
stabilize it is the lack of a structural information about LPL. When I set out to develop 
a single molecule FRET-constrained model, I was hoping to resolve this issue. From 
the models we generated, there were two major structural orientations for the dimer 
(see previous chapter) supported by my data. The structural model that is supported 
by previous studies is one that encompasses elements of models A and B along with 
the third HADDOCK model. These models appear to be extremes of the best LPL 
model that fits the head-to-tail conformation. They are broadly similar to each other 
and to the previously published LPL dimer models, but differ enough to have 
significantly different distances. Moving towards a better “blended” model in which 
the long chain substrate binding site is near the active site requires consideration of 
the populations present for each set of mutants. 
 When I first evaluated data, I only had data from the LPLV224C combinations, 
which both strongly supported Rosetta models A and B over the HADDOCK model. 




suggested a divergence from the two Rosetta models. The data shown in Chapter 3 
suggests a model in which LPLS384C and LPLS36C on one monomer are 
approximately the same distance from LPLS384C on the other, most like the 
HADDOCK model. Inspection of the histograms for these later pairs reveal that the 
major population of LPLS384C to LPLS384C is skewed towards longer, lower FRET, 
distances while the major population for LPLS384C to LPLS36C appears to be skewed 
towards shorter. This supports a “middle ground” between Rosetta models A and B 
and the third HADDOCK model, with the dimer being slightly more shifted in favor of 
S36C being shorter than S384C to itself.  With the data from LPLV224C pairs being 
longer than the HADDOCK model, it seems likely an outward rotation along the X-
axis for both dimers would be needed to increase the space between the partners, in 
addition to the translation along the X-axis to correctly position LPLS384C and LPLS36C.   
I am currently working with a collaborator to add dyes into the models and 
improve upon the models by constraining them with the dye distances I have 
generated. This new model will provide the first truly experimentally supported 
structure. 
 
Future Directions for Single Molecule Experiments 
In my studies using smTIRF in Chapter 3, I describe methods and 
experiments that I devised to address just a few outstanding questions about LPL. 
There are many future advancements and tricks that could be used to make this 




several outstanding questions about LPL that will greatly benefit from single 
molecule studies. I briefly discuss these future directions below. 
 
Future Advancements in the Experimental Setup 
I provide one suitable method of attachment for LPL to slides, but several 
other interesting possibilities open the door for more studies. One major 
advancement would be using biotin-PEG functionalization instead of BSA, to reduce 
non-specific binding. The Erie Lab has recently adopted this protocol with the 
availability of a reasonably affordable non-fluorescent PEG stock. This attachment 
method should be utilized in future studies, especially those aimed at measuring 
regulatory factor interactions with LPL. 
Another way surfaces are often functionalized is by encapsulating protein in 
biotinylated liposomes. As mentioned in Chapter 3, this is not a good idea for 
encapsulating an active lipase, however it would be an excellent way to visualize 
LPL’s interaction with fluorescently labelled apolipoproteins added to the surface of 
the liposomes, representing mimetic lipoproteins. Lipoproteins could also be 
potentially biotinylated and utilized in the same manner.  
 
LPL – Apolipoprotein Interactions 
Using the liposome attachment method mentioned above, the possibility to 
measure LPLs interaction with lipoproteins is endless. One major advantage with 
attaching the lipoproteins to the slide is that LPL could be added to the slide in real-




cold and stable longer than if it is attached to the slide, an advancement that will 
increase the number of active molecules undergoing FRET. 
Two of the apolipoproteins that would be particularly interesting to study are 
the LPL inhibitor APOC-III and LPL activator APOC-II, which both work by unknown 
mechanisms. One recent paper suggests that APOC-III inhibits LPL through 
displacement of LPL from the surface of lipoproteins(41). To further investigate this 
mechanism, fluorescent APOC-III could be bound to biotinylated liposomes on a 
surface, and then fluorescent LPL flowed over the surface to determine if APOC-III 
leaves with LPL when it binds. This would be an elegant experiment that would 
directly show what happens when APOC-III and LPL interact. 
Using a similar experimental setup, APOC-II could also be studied. Recent 
studies have shown a renewed interest in LPL’s most abundant activating factor, 
APOC-II. Little is known about how APOC-II activates LPL, apart from APOC-II 
supporting substrate turnover(33). One likely mechanism for this is through 
modulating substrate access by LPL’s lid. If and how APOC-II alters LPL’s lid 
movement would be very interesting, especially since small lid dynamics were 
observed in my study of the lids undergoing FRET in Chapter 3. Adding back 
fluorescent APOC-II(36,67) to APOC-II-deficient lipoproteins and seeing how this 
impacts lid movement, if at all, will help support a model for creating the most 







Visualizing LPL’s Lid Movement 
As mentioned above, small transitions were observed when the LPL Lid 
mutant, LPLV224C was bound to itself. LPL’s substrate hydrolysis is mediated, like 
most lipases, by its lid, but how LPL’s lid functions to govern substrate entry remains 
a mystery. In vitro activity assays reveal that LPL can hydrolyze short chain 
substrates in the absence of a full-length lid, supporting a hypothesis that LPL’s lid 
does not mediate hydrolysis, but instead is more important for substrate specificity. 
In my data, some transitions showed a decrease in FRET while others showed an 
increase, suggesting one monomer’s lid was moving slightly in the opposite direction 
of the other with no definite pattern. The movement in LPL’s lid may represent LPL 
sampling available space for suitable substrates. I have a single trace of preliminary 
data, not included here, in which an LPL dimer undergoes FRET in the presence of 
TRLs. In this trace, the FRET seems to increase steadily and then sharply drop 
several times over the course of the trace, perhaps suggesting LPL’s lid is opening 
and closing. Extensive studies will need to be conducted in the future to see if the 
data I showed can be recapitulated, especially in the presence of fluorescently 
labelled lipoproteins. If LPL’s lid is required to open and close for each cycle of 
substrate hydrolysis, this suggests that a small molecule aimed at holding LPL’s lid 
open is not a suitable therapeutic.  
 
Single Molecule Studies to Reveal ANGPTL3 and ANGPTL8 Mechanics 
Here, I showed that ANGPTL4 binding to LPL occurs over a short lifetime 




and ANGPTL8, also interact with LPL on a similar timescale. It was recently shown 
that in vivo, you need ANGPTL3 for ANGPTL8 to be active while ANGPTL3 can act 
independently(49). The structural and oligomeric requirements for this inhibition 
remain a mystery. While our lab was able to visualize ANGPTL4 tetramers bound to 
LPL dimers using AFM(53), it would be hard to distinguish ANGPTL3 and ANGPTL8 
from each other via AFM. SmTIRF could thus be used to monitor complex binding 
where the ANGPTLs are labeled with two distinct dyes such that the stoichiometry 
and binding dynamics could be determined. This detail could not be observed using 
SPR or other available biochemical techniques. 
 
Conclusions 
 In conclusion, LPL is a revolving therapeutic target with many angles for 
pharmaceutical intervention. In this thesis, I highlighted how biochemistry was 
necessary to explain how a gain-of-function LPL mutant, LPLS447X and I provide a 
new approach to biochemically characterizing LPL, single molecule fluorescence, 
and use that technique to move towards a better model of the LPL dimer. Single 
molecule studies, in addition to the new dimer model, will open a wide possibility for 
different studies imagined here, as well as by others.  
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